Phase 1 Myeloma Trial, Recruiting (NCT06435910)

Phase 1 Myeloma Trial, Recruiting NCT06435910 Sponsor: Shenzhen Geno-Immune Medical Institute Condition: Myeloma

Printed from Voxsanity (voxsanity.com.au) — NCT06435910 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myeloma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with multiple myeloma or plasmacytoma (types of blood cancer)
People whose cancer has responded very well or completely to previous combination treatments
People whose doctors expect them to survive for more than 12 weeks
People who have suitable veins for blood draws or a procedure to collect blood cells (apheresis), and no medical reasons preventing blood withdrawal
People who are willing to give their informed consent and to attend follow-up appointments

Who may not be able to join:

Women who are pregnant or currently breastfeeding
People who have an active infection that is not under control
People who have HIV, or an active hepatitis B or hepatitis C infection
People who are currently taking steroid medicines in tablet or injection form (note: steroid inhalers, such as those used for asthma, are not a reason for exclusion)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 12 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 0755-86573763

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06435910

Sponsor: Shenzhen Geno-Immune Medical Institute

Phase: Phase 1

Status: Recruiting

Condition: Myeloma

Trial contact: +86 0755-86573763

More information: https://clinicaltrials.gov/study/NCT06435910

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with multiple myeloma or plasmacytoma (types of blood cancer)
People whose cancer has responded very well or completely to previous combination treatments
People whose doctors expect them to survive for more than 12 weeks
People who have suitable veins for blood draws or a procedure to collect blood cells (apheresis), and no medical reasons preventing blood withdrawal
People who are willing to give their informed consent and to attend follow-up appointments

Who may not be able to join:

Women who are pregnant or currently breastfeeding
People who have an active infection that is not under control
People who have HIV, or an active hepatitis B or hepatitis C infection
People who are currently taking steroid medicines in tablet or injection form (note: steroid inhalers, such as those used for asthma, are not a reason for exclusion)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 12 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Shenzhen Geno-Immune Medical Institute

Registry

ClinicalTrials.gov

Start date

11 May 2024

Est. completion

11 July 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Safety of DC injection

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov